The US Food and Drug Administration (FDA) has postponed the decision on Roche’s new drug application (NDA) of risdiplam to treat spinal muscular atrophy (SMA).

The decision is now set to be made by 24 August, on contrary to previously expected 24 May.

According to Roche, the delay is due to the recent submission of additional data, including results from the SUNFISH Part 2 clinical trial.

The drug received priority review designation from the FDA last November. After discussions with the FDA in February, the company submitted additional data to enable the use of the drug in a broader patient population.

Roche chief medical officer and Global Product Development head Levi Garraway said: “We strongly believe in the potential of risdiplam as a new therapeutic option and recognise that unmet need remains in the treatment of SMA.

“We are working closely with the FDA to support the review of risdiplam. Our goal is to bring this therapy to infants, children and adults living with SMA as quickly as possible.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Risdiplam is an oral, experimental survival motor neuron-2 (SMN2) splicing modifier that acts by increasing and maintaining SMN protein levels in the central nervous system and peripheral tissues.

The drug’s clinical development is led by Roche under an alliance with the SMA Foundation and PTC Therapeutics.

Currently, the drug is being studied in SUNFISH trial in patients aged 2-25 years with types 2 or 3 SMA, and FIREFISH trial in infants with Type 1 SMA.

In addition, JEWELFISH trial involves patients aged 6 months to 60 years who previously received SMA-directed therapies.

As well as the US, Roche filed applications in Brazil, Chile, Indonesia, Russia, South Korea and Taiwan. The company will also seek approval in China and the European Union, among other markets.